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Summary.-Administration of ovine prolactin alone supported growth of hormone-
dependent GR mouse mammary tumours. Growth ofhormone-independent tumours
was not stimulated. Furthermore, administration of bromocriptine, a compound that
inhibits release of prolactin from the pituitary gland, was shown to inhibit the growth
of hormone-dependent tumours in animals receiving treatment with progesterone +-
oestrone. Administration of prolactin or bromocriptine to mice bearing tumours
that grew independently of progesterone + oestrone treatment had no influence on
tumour growth. We conclude that direct as well as indirect evidence has been found
for the involvement of prolactin in the growth of transplanted, hormone-dependent
GR mouse mammary tumours.
CLINICAL results have demonstrated
the importance ofoestrogens in the growth
regulation of some breast cancers (Jensen
et al., 1973). Other hormones, such as
)rolactin, may be involved in the growth
of mammary cancer. Prolactin is already
known to be essential for the growth of
many rat mammary tumours (for review,
see Boyns and Griffiths, 1972).
This communication demonstrates,
directly and indirectly, that prolactin
supports growth of transplantable GR
mouse mammary tumours that grow in
spayed mice treated with progesterone
plus oestrone and do not grow in untreated
spayed mice.
MATERIALS AND METHODS
Chen icals. Progesterone and oestrone
were generously provided by Leo Pharma-
ceuticals, Ballerup, Denmark. Bromocrip-
tine (2-Br-a-ergokryptine-methanesulphonate)
-was donated by Sandoz, Basel, Switzerland.
Ovine prolactin (20-25 iu/mg) wNas supplied
by Ferring AB, Malmo, Sweden. The
remaining, chemicals w-ere of analytical grade.
Tumour mlodel. Mammary carcinomas
were induced in spayed mice ofthe GRS/AFib
strain according to the method of van Nie
(personal communication, 1970). Ten-to-12-
week-old female mice were spayed and im-
mediately treated with progesterone plus
oestrone (p + o). Progesterone pellets pre-
pared from a paste of progesterone and olive
oil were injected s.c. once a week at, a dose of
5-10 mg. Oestrone was dissolved in ethanol
and added to the drinking water (redistilled
water) at a concentration of 0-5 ,ug/ml.
S.c. transplantation of induced tumours
was carried out using either minced tumour
tissue or tumour cells isolated enzyTmat,ically
according to the method ofWiepjes and Prop
(1970) modified by excluding the use of
DNAse. Each animal received either 100 1l
of minced tumour tissue or 7-20 x 106
tumour cells.
Hormone-dependent (HD) tumours Aere
defined as tumours that gromw progressively
in (p + o)-treated spayed mice but not in
untreated spayed mice. Hormone-indepen-
dent (HI) tumours, on the other hand, grow
* Patt of this woik has been presentedl at the Secoindl -Meeting of the European Association for Cancer
Resc'arch, Hcidelberg, 1973, an(d the Xth Acta Endocrinologica Congress, Amsterdam, 1975.
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equally well in (p + o)-treated and untreated
spayed animals.
Ovine prolactin was dissolved in 50 mm
sodium bicarbonate, pH 9-85, to yield a final
concentration of 0-5 mg/ml. Aliquots -were
stored at -20TC. 0 5 mg prolactin w%Nas
injected i.p. 3 x daily at 6-10-h intervals.
Bromocriptine was dissolved in ethanol,
diluted 1/10 in H20, and 0-2 mg in 100 yul
-was administered s.c. daily.
Experiments with prolactin. Grow th of
both HD and HI tumours was investigated
during administration of prolactin. All the
HD tumours were in the first transplant
generation, while the HI tumours ere either
in the first or in the eighth transplant genera-
tion. In each experiment, 13-24 spayed mice
received transplants of the same tumour.
WXhen the transplants had formed a tumour
of 0 5-1 cm3, p + o administration was
discontinued in the experiments -with HD
tumours. Although the effects of proges-
terone are evident in the vaginal smear up to
4 weeks after implantation of 3 mg proges-
terone (Rdpcke, 1975), the tumours regressed
to half size within 1-2 weeks. At that time
the animals were divided into 3 or 4 groups of
3-6 animals and treated as follows:
G'roup I, p + o: 5-10 mg of progesterone (3
pellets) s.c. per week + 0 5 ytg/ml of
oestrone in the drinking ater.
Group II, prolactin: 50 ,ug (100 1u) of pro-
lactin i.p. 3 x daily at intervals of
6-10 h.
G1roup III, controls: 100 ,ul of bicarbonate
buffer i.p. 3 x daily at intervals of
6-10 h.
G'roup IV, p + o + prolactin: p + o treat-
ment as in Group I, and prolactin treat-
ment as in Group II.
Tumour growth was followed by measur-
ing the size ofthe tumours with a slide caliper,
as described by Rockwell, Kallman and
Fajardo (1972). When the largest tumour in
each group reached 1-2 cm3 in size, all
animals in the experiment were killed.
The experiments with HI tumours were
carried out in the same -way, with the
modifications necessary with HI tumours.
Thus, all mice received p + o treatment until
the tumours had attained a volume of 0 25-
0*5 cm3. At this time, mice mwere divided into
the above treatment groups (with the omis-
sion of Group IV), and tumour size -was
monitored as described above.
Experiments wvith bromocriptine.-Six
mice were spayed for each of 5 experiments
with HD tumours and immediately treated in
the following manner: 2 were treated with
p + o as above, 2 with p + o + bromocrip-
tine (0-2 mg s.c. per day), and 2 untreated.
One week later, tumour tissue from a single,
primary tumour was transplanted to each of
the 6 animals. HI tumours were transplanted
to 4 animals only, 2 receiving treatment with
bromocriptine and 2 untreated.
The animals were observed twice weekly.
When the largest tumour reached approxi-
mately 1 cm3 in size, all animals within the
single experiment were killed, and the
tumours were removed and weighed.
Statistics
Statistical evaluation wAas performed writh
the non-parametric Wilcoxon rank-sum test.
RESULTS
The effects of prolactin, p + o +
prolactin, and p + o, on regrowth of
regressing HD mammary tumours, were
studied in 6 experiments. The results
are shown in Fig. 1. In all 6 experiments,
treatment with prolactin alone supported
tumour growth for several days, whereas
tumours continued to regress in all
control mice injected only with buffer. In
each of the experiments, the final volume
of the tumours in the prolactin-treated
group was significantly higher (P < 0 01)
than that of the tumours in the control
groups. Futhermore, prolactin signifi-
cantly stimulated (P < 0 02) (p + o)-
supportedtumourgrowthin 1 (Experiment
D) of 3 experiments. Administration of
prolactin had no significant effect (P >
01d0) on the growth of HI tumours
(Fig. 2).
The growth of HD tumours trans-
planted to spayed mice receiving bromo-
criptine + p + o was studied in 5
experiments. In all of these, mean
tumour volume was lower in animals
treated with bromocriptine + p + o than
in controls treated with p + o alone (Fig.
3). This difference is statistically sig-
nificant (P < 0.05) as tested by the
817P. BRIAND, S. M. THORPE, AND J. L. DAEHNFELDT
K I]3. CONTROLS I-. P+O+PROLACTIN lo
-
L4
0.6
04
o 2 4 6 8 0 2 4 6 8 lo
DAYS
FIG. 1.-Effect of administration of prolactin
and/or p + o on growth of HD mammary
carcinomas in spayed GR mice. All
tumours were in the first transplant gener-
ation. Administration of p + o to spayed
mice bearing HD tumours was discontinued
when tumours reached 0-5-1 cm3. Sub-
sequently, tumours began to regress. 1-2
weeks later (Day 0), the animals were
divided into the following groups for treat-
ment with various hormones. I: 5-10 mg
of progesterone (p) pellets s.c. weekly +
0-5 ,ug/ml of oestrone (o) in the drinking
water. II: 50 ,ug (100 ,ul) ofprolactin i.p.3
x daily at intervals of 6-10h. III: 100 ,u
ofbufferi.p. 3 x daily at intervals of6-10h.
IV: p + o as in I + prolactin as in II.
Relative tumour volume is defined as
Tumour volume at a given time
Tumour volume at Day 0
Each point on the curves represents the
median of 5-6 tumours, except Expt. B,
Group I, in which only 3 mice are included.
The range of relative tumour volume at the
end of each experiment is shown by bars.
Wilcoxon rank-sum test based on allsingle
observations shown in the figure. Thus
the zero value in Experiment 5 is also
included. No tumour takes were
observed in the untreated mice. In
contrast, when HI tumours were trans-
planted to mice receiving bromocriptine,
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FIG. 2.-Effect of administration of prolactin
or p + o on growth of HI mammary
carcinomas in spayed GR mice. Tumours
ofExpt. G were in the 1st transplant gener-
ation, and tumours of Expt. H in the 8th
transplant generation. When HI tumour
transplants had attained a volume of 0-25-
0-5 cm3 (Day 0), the mice were divided
into the following groups for treatment
withhormones: I: 5-10mgofprogesterone
(p) pellets s.c. weekly + 0-5 ,ug/ml of
oestrone (o) in the drinking water. II: 50 ,ug
(100 j1l) of prolactin i.p. 3 x daily at
intervals of 6-10 h. III: 100 ,ul of buffer
i.p. 3 x dailyatintervalsof6-10h. Relative
tumour volume is defined as
Tumour volume at a given time
Tumour volume at Day 0
Each point on the curves represents the
median of 5-6 tumours. The range of
relative tumour volume at the end of each
experiment is shown by bars.
tumour growth in treated mice did not
differ from that in the untreated, control
mice (Fig. 4). In Experiments 9b and
lOb, bromocriptine seemed to inhibit
tumour growth, but in duplicate experi-
ments with the same tumour line, this
did not appear to be the case (Experiments
9a and lOa).
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FIG. 3. Growth ofHD mammary carcinomas
in spayed GR mice treated with p + o
(open circles) or p + o + bromocriptine
(closed circles). All tumours were in the 1st
transplant generation. Ineachexperiment,
one primary tumour was transplanted to 6
spayed mice, 2 receiving 5-10 mg of pro-
gesterone (p) pellets s.c. weekly + 0-5jig/ml
of oestrone (o) in the drinking water, 2
receiving p + o + daily injections of 0-2 mg
bromocriptine s.c., and 2 untreated. The
number of days that tumour-bearing mice
received treatment is shown below the
Fig. The open and closed circles denote
mean tumour weight of 2 tumours, the
individual weights of which are indicated
by the ends of the bars. No tumours were
observed in untreated spayed mice at the
end ofthe experiment (not shown in Fig.).
DISCUSSION
The importance of prolactin in
mammary tumour induction has
previously been established in rats and
mice by demonstrating a significantly
higher tumour incidence under various
conditions leading to increased serum
prolactin levels (Boot, 1970; Meites, 1972),
and by demonstrating a significantly
lower tumour incidence during admini-
stration of bromocriptine, an inhibitor of
prolactin secretion (Stahelin, Burckhardt-
Vischer and Fliickiger, 1972; Yanai and
Nagasawa, 1972; Welsch and Gribler,
1973; Chan and Cohen, 1974).
FIG. 4. Growth of HI mammary carcinomas
in spayed GR mice, untreated (open circles)
or treated with bromocriptine (closed
circles). In Expts 7-8, 1 tumour, and in
Expts 9-11, 2 tumours (a and b), were each
transplanted to 4 spayed mice, 2 untreated
and 2 given daily injections of 0-2 mg
bromocriptine s.c. The number of days
that tumour-bearing mice received treat-
ment is shown below the Fig. The open
and closed circles denote mean tumour
weight of 2 tumours, the individual weights
ofwhich are indicated bytheendsofthebars.
Prolactin has also been shown to
stimulate the growth of pre-existing
mammary tumours in DMBA-treated rats
(Pearson et al., 1969; Welsch, Clemens and
Meites, 1969; Nagasawa and Yanai, 1970;
Leung and Sasaki, 1975). Furthermore,
when prolactin secretion is diminished in
carcinogen-treated rats (by administration
of bromocriptine), mammary tumour
growth has been found to be inhibited
(Heuson, Waelbroeck-Van Gaver and
Legros 1970; Nagasawa and Meites,
1970).
In the mouse, the role of prolactin in
mammary tumour growth has been less
thoroughly investigated. Most mouse
mammary tumours are HI (Miihlbock,
1955). However, in a few inbred strains,
such as the BR strains (Foulds, 1949), the
DD strain (Heston, Vlahakis and Tsubura,
2 x
Exp. no. 2 3
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1964), the RI1I strain (Squartini, 1962),
and the G(R strain (van Nie and Thung,
1965), the incidence of pregnancy-
responsive mammary tumours is very
high. Studies of the effects of pregnancy
and pseudo-pregnancy on mammary
tumour induction and growth in BR6 mice
indicated that the hormones of late
pregnancy were important for the induc-
tion ofnew tumours, whereas the hormones
of early pregnancy stimulated the growth
of existing tumours (Lee, 1970). Since
prolactin levels are high in early pregnancy
in the mouse (Murr, Bradford and
(Xeschwind, 1974), it is feasible that
prolactin is involved in the growth of
these pregnancy-dependent tumours.
The finding in BR6 mice that 4/7 tumours
induced by grafting pituitary glands
under the kidney capsule ceased to grow
after removal of the graft-bearing kidney,
offers further indication for the involve-
ment of prolactin in the growth of mouse
mammary tumours.
In the GR strain of mice, mammary
tumours can be induced by forced
breeding (van Nie and Dux, 1971) or by
treatment of spayed mice with p + o (van
Nie, personal communication,). Most of
the mammary tumours induced by p + o
treatment are dependent upon the
continued administration of p + o for
growth (Briand and Daehnfeldt, 1973;
Sluyser and van Nie, 1974). Since long-
sustained administration of oestrogens
is known to lead to enlargement of the
pituitary gland and increased production
of prolactin in mice (Kim, Furth and
Yannopoulos, 1963; Boot, Kwa and
Rdpcke, 1973; Chan and Cohen, 1974)
prolactin might be involved in the stimula-
tion of growth of these (p + o)-dependent
GTR mouse mammary tumours.
We have found that administration of
prolactin alone leads to regrowth of
regressing GR mouse mammary tumours.
The growth rate of tumours in mice
treated with prolactin was not, however,
as great as that in the (p + o)-treated
mice. This may have been due to use of
heterologous prolactin or maintenance of
suboptimal levels of prolactin through-
out part of the experiment. Provided
that the half-life of prolactin in mice is of
the same order as that found in rats (Kwa
et al., 1970), very low prolactin levels
would have prevailed, in spite of the fact
that a very high dose of prolactin was
administered. Yet another possible ex-
planation for the above observation would
be that prolactin may require oestrogen
to exert its maximal effect on tumour
growth, or vice versa. However, while the
effects of p + o + prolactin on tumour
were additive in 1/3 experiments (Fig. ],
experiment D), a potentiation of the
hormone effects was not observed.
(p + o)-dependent growth was in-
hibited by bromocriptine. In 4/5 experi-
ments (bromocriptine + p + o)-treated
animals showed lower values than (p + o)-
treated controls, without any overlapping
(see Fig. 3). In the fifth experiment one
of the control mice for unknown reasons
did not develop any tumour. The other
one produced a tumour which weighed
more than the tumours in the 2 mice which
received bromocriptine.
When the results of all 5 experiments
were evaluated by the Wilcoxon rank-sum
test the inhibitory effect of bromocriptine
was found to be statistically significant.
An unspecific, toxic effect ofbromocriptine
on tumour growth is unlikely but cannot
be excluded, since animals bearing HD
tumours were treated with bromocriptine
for a longer period of time than animals
bearing HI tumours.
A difference in time of treatment was
unavoidable, since the same amount of
tumour tissue was transplanted to each
mouse, and the treatment period was not
extended beyond the exponential growth
phase of the tumour.
In conclusion, evidence has been
presented for the involvement of prolactin
in the growth of transplanted, hormone-
dependent GR mouse mammary tumours.
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